To evaluate the potency recovery after 1 year follow up in patients undergonechitosan membrane (ChiMe) application on neuro-vascular bundles (NVB) during nerve-sparing (NS) robot-assisted radical prostatectomy (RARP). To compare the results with those of a contemporary cohort of patients who had not benefited from chitosan use.
INTRODUCTION AND OBJECTIVES:
To evaluate the potency recovery after 1 year follow up in patients undergonechitosan membrane (ChiMe) application on neuro-vascular bundles (NVB) during nerve-sparing (NS) robot-assisted radical prostatectomy (RARP) . To compare the results with those of a contemporary cohort of patients who had not benefited from chitosan use.
METHODS: We enrolled patients undergone NS-RARP with ChiMe applied on the NVB from July 2015 to September 2016 in a preliminary phase II study. They were followed to complete one-year follow-up. The control group was composed of patients who underwent NS-RARP without the application of ChiMe in the same period of time. The patients were stratified into two groups on the basis of the amount of nerves spared: group A, patients who benefited from a monolateral or a bilateral full NS; group B, patients in which a full NS was not performed. The demographics, perioperative, and postoperative data, and complications, were collected. Potency recovery rate was recorded in both groups.
RESULTS: 136 patients were enrolled in the ChiMe group, with 334 patients in the control group. Both groups were comparable in terms of baseline variables. On the basis of nerve sparing, 183 patients were included in group A, with 287 in group B. Odds ratios at different time points showed that the only two factors influencing the potency recovery were the amount of nerves preserved (group A v. group B) and the application or not of ChiMe on the NVBs spared. A statistically significant improvement of the potency recovery rate in the ChiMe group v. Control group was found at one (36.76% vs 25.88%; p[0.02) and two (52.2% vs 39.22%; p[0.01) months after surgery, moreover we recorded a favorable trend at every time point of the whole follow-up period, even if not significant after the second postoperative month. As concerns group A, the Log-Rank test showed a statistically significant difference between ChiMe v. control group (p[0.02), in particular at one and two months after surgery (p[0.02 and p[0.01, respectively) .
CONCLUSIONS: The application of ChiMe on the NVBs resulted in a higher potency recovery rate at one and two months after a bilateral or monolateral full NS RARP. A trend towards a faster recovery of erectile function in the ChiMe groups was recorded at every time point, even in the cohort of patients who underwent a non-full NS procedure.
Source of Funding: none

MP66-07 OMITTING A LYMPH NODE DISSECTION AT RADICAL PROSTATECTOMY: ARE THERE CONSEQUENCES FOR UNEXPECTED UPGRADING/UPSTAGING?
Muammer Altok, Brian Chapin, Surena Matin, Mary Achim, John Davis*, Houston, TX INTRODUCTION AND OBJECTIVES: Patients with low to favorable intermediate risk prostate cancer (or using a nomogram) may be selected for a radical prostatectomy treatment without a lymph node dissection. However, some patients may then experience upgrading or upstaging above such threshold-a term we have given "Nx Regret." In this study, we explore the hypothesis that patients with Nx Regret pathology experience the same vs different biochemical relapse relate compared with a matched cohort of pN0/N1 selected cases.
METHODS: The patient population is from an NCI designated comprehensive cancer center with multi-surgeon, high-volume experience in robotic prostatectomy and extended lymphadenectomy. Patients studied were treated from 2006-2012 to allow sufficient PSA follow-up. We constructed the study cohort of 521 pNx and 505 pN0/ N1 patients with biopsy Gleason score 3þ4 and cT1c-cT2. Cohorts were compared unadjusted and then with propensity score matching.
RESULTS: Gleason upgrading from 3þ4 to RP Gleason grade >3þ4 and/or pT3-4 was observed in 17% of pNx (Nx Regret) and in 32% of pN0/N1 (p <0.001). BCR occurred in 5% in the Nx, and 7% in the PLND group. Five-year BCR free survival rate was higher in the Nx group (94.7% vs. 91%, p [ 0.048) . In the pNx group, Nx Regret and non-Nx Regret were compared. BCR occurred in 3% in the non-Nx Regret and 18% in the Nx Regret patients. Five-year BCR free survival rate was higher in the Non-Nx Regret group (98% vs. 81%, p <0.001). Finally, Nx Regret was compared with propensity score matched PLND (N0/N1) patients. Five-year BCR free survival rate was detected similar between groups (81% vs. 83%, p [ 0.467, Fig.1) .
CONCLUSIONS: When low to favorable intermediate risk patients are selected for no PLND and experience upgrading or upstaging, they have a higher predicted BCR. However, when matched to similar patients with pN0/N1, the BCR was not different. We did not identify a testable hypothesis that the PLND adds therapeutic value in this patient group.
Source of Funding: This study was supported in part by Cancer Center Core Grant (P30CA 16672) from the University of Texas MD Anderson Cancer Center.
